Solicitor General sides with reps in GSK overtime case

GSK in biggest-ever $3b marketing fraud settlement
GSK in biggest-ever $3b marketing fraud settlement

The U.S. Solicitor General has filed an amicus brief taking the side of two pharmaceutical sales reps in the overtime case that they filed against GlaxoSmithKline.

The lawsuit alleges that the company denied the sales reps overtime pay by improperly considering them as outside salesmen. The term is defined by the Department of Labor, which also has definitions that distinguish between sales and promotional work.

The Solicitor General's brief argues that the plaintiffs fall into the promotional category, because unlike salesmen, they cannot take orders, negotiate prices or determine a patient's best interest—the latter being a physician's job.

The brief concedes that the drug reps could be considered salesmen, even if only in a colloquial sense, “because they seek to persuade physicians.”

GSK has argued that the sales reps trigger sales, but the Solicitor General's brief says that the restrictions which surround a drug rep's practice make it “impossible to determine with certainty whether a PSR's promotional work induced any particular prescription.”

Novartis settled a suit similar to the GSK case in January, for $99 million, and Schering-Plough was found to owe overtime pay in August.

The Supreme Court is scheduled to hear the sales rep/GSK appeal in the session beginning on April 16.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.